In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Rashmi DahiyaChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-7985-0862 Ianthe A E M van BelzenEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridge, UK.ORCID 0000-0003-2377-3586 Chengheng LiaoDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-9073-3835 Angad KumarDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-9535-3620 Yu-Fen LinChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0003-2755-9317 Ahyeon KoChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Amanda K MennieChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Emilija AleksandrovicDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-6698-2893 Jin ZhouDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Qing HuDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Justin L EngelDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-2016-3494 Jeffrey MiyataDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jose Espejo Valle-InclánEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridge, UK.ORCID 0000-0002-4857-5984 Alistair G RustEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridge, UK.ORCID 0000-0001-7287-192X Ravikanth MaddipatiDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-0317-1361 James BrugarolasDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-8575-499X Srinivas MalladiDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Siyuan ZhangDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0003-0910-3666 Payal KapurDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-4239-0495 Qing ZhangDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Isidro Cortés-CirianoEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridge, UK.ORCID 0000-0002-2036-494X Peter LyChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-8946-7069 Funding
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7MUniversity of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Payal Kapur, Payal Kapur · 2016 to 2026
$24.7MNew Von Hippel Lindau (VHL) tumor suppressor signaling in renal cancerR01CA294636 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Qing Zhang · 2024 to 2026
$2.7MGenomic Instability from Fragmented Chromosomes in MicronucleiR35GM146610 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI Peter Ly · 2022 to 2026
$2.3MccRCC Metastatic Competency DeterminantsR01CA258629 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Srinivas Malladi · 2022 to 2026
$2.0MMechanisms of Chromosome Shattering from Defective DNA ReplicationR01CA289435 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Peter Ly · 2024 to 2026
$1.3MNCI NIH HHS P30 CA142543NCI NIH HHS P50 CA196516NCI NIH HHS R01 CA258629NCI NIH HHS R01 CA289435NCI NIH HHS R01 CA294636NIGMS NIH HHS R35 GM146610
6 · The paper itselfAbstract
Clear cell renal cell carcinoma (ccRCC) is initiated by chromosome 3p loss, yet chromosome losses impose a profound fitness burden on normal cells. How renal epithelial cells tolerate this deleterious aneuploidy during early tumorigenesis remains unclear. Analysis of 949 ccRCC genomes reveals two major classes of chromosome 3p alterations: simple deletions and complex rearrangements surrounding a terminal breakpoint - a pattern we term breakpoint-confined chromothripsis. We modeled both alterations in non-transformed human renal proximal tubule epithelial cells by introducing a single DNA double-strand break on chromosome 3p. Despite an initial fitness disadvantage, chromosome 3p loss drives adaptive genomic evolution that recapitulates recurrent ccRCC-associated aneuploidies, including 5q gain and 14q loss. These alterations alleviate the fitness constraints of 3p loss and promote metabolic reprogramming, clonal expansion, and malignant transformation, producing tumors with features of ccRCC. Thus, a single chromosome break initiates the evolutionary trajectory of ccRCC by creating a fitness bottleneck that selects for recurrent aneuploidies.
Indexed as
adaptive aneuploidybreakage-fusion-bridgecancer evolutionchromosomal instabilitychromosome 3p losschromothripsisclear cell renal cell carcinomamicronucleitumor initiation
Identifiers
PMID42465403
PMCPMC13371068
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390